Expectations High Around AcelRx Pharma’s (ACRX) Drug; AMREP (AXR) Posts Strong Earnings Growth


AcelRx Pharmaceuticals Inc. (Nasdaq:ACRX) shares soared more than 15% in the extended session Wednesday after the company said that it will release (before the opening bell rings on Thursday, September 15) top-line data from a late stage study evaluating its non-invasive investigational drug ARX-04 in patients with post-operative moderate-to-severe acute pain

ACRX stock closed at $3.28, up $0.06 (or +1.86%) and 179,691 of its shares changed hands during the day

AcelRx Pharmaceuticals, which develops and commercializes therapies for the treatment of acute pain, has 45.31M Shares Outstanding and ACRX stock 52-wek range is from $2.40 to $5.88 per share. At close on Wednesday, the company had a Market Capitalization of $148.62M



AMREP Corp. (NYSE:AXR) delivered after the closing bell Wednesday strong financial performance in its quarterly earnings report.

For its first quarter fiscal 2017, AMREP posted revenues of $12.21 million, a 27.49% increase year over year, and net income of $630,000, or $0.08 per share versus a net loss of ($1.18) million, or ($0.15) per share in the same period the prior year

AXR stock finished the regular session in negative territory by 0.54% (or -$0.04) at 7.36 with a total volume of 12,013 shares traded

AMREP, a real estate and media services company, has 8.07M Shares Outstanding, Market Capitalization (intraday) of $59.41M and AXR stock one-year range is between $3.66 and $7.80 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/